德恒上海律师事务所 关于 上海康德莱企业发展集团股份有限公司 2025 年第二次临时股东会之 见证意见 上海市东大名路 501 号上海白玉兰广场办公楼 23 层 电话：021-55989888/55989666 传真：021-5598 9898 邮编：200080 德恒上海律师事务所 关于上海康德莱企业发展集团股份有限公司 2025 年第二次临时股东会之见证意见 见证意见 德恒 02G20170018-00035 号 致：上海康德莱企业发展集团股份有限公司 德恒上海律师事务所接受上海康德莱企业发展集团股份有限公司（以下或称 "公司"）的委托，指派本所见证律师对公司于 2025 年 11 月 13 日 10:00 召开 的 2025 年第二次临时股东会（以下简称"本次股东会"）进行见证并出具本见 证意见。 本所见证律师依据本见证意见出具日前已经发生或存在的事实和《中华人民 共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以 下简称"《证券法》"）、《上市公司股东会规则》（以下简称"《股东会规则》"） 等现行有效的法律、法规和规范性文件以及《上海康德莱企业发展集团股份有限 公司章程》（以下简称 ...

Core Viewpoint - The company is actively working on its business operations in the fourth quarter while also planning and budgeting for next year's operational goals and preparations [2] Group 1 - The company is making continuous efforts to advance its business operations during the fourth quarter [2] - The company is in the process of planning and budgeting for its operational goals for the upcoming year [2] - Preparations for various operational activities for next year are being arranged and deployed [2]

Core Viewpoint - The company is actively monitoring domestic and international industry trends while effectively executing its strategic goals, enhancing its operational capabilities across market, research and development, and manufacturing sectors [1] Group 1 - The company is focused on continuously consolidating and improving its operations [1]

Core Viewpoint - The company, Kangdelai (603987), stated that its operations are normal, and fluctuations in customer orders and turnover rates are within a controllable range [1] Group 1 - The company confirmed that its business operations are functioning normally [1] - Customer orders are experiencing fluctuations, but these are deemed normal and manageable [1] - The turnover rates are also within a controllable range, indicating stability in operations [1]

Core Viewpoint - The company, Kangdelai (603987), is actively maintaining good cooperation with many excellent clients and partners while promoting projects in medical engineering and industry-academia-research collaboration [1] Group 1 - The company is engaging in active communication with investors through interactive platforms [1] - The company emphasizes its commitment to fostering partnerships and collaborations in various projects [1]

Core Viewpoint - The company, Kangdelai (603987), is actively evaluating its strategic goals and operational execution through a SWOT analysis, aiming for healthy and high-quality development while implementing targeted strategic guidance across its subsidiaries [1] Group 1: Strategic Planning - The company has conducted a SWOT analysis to assess its current strategic execution and identify areas for improvement [1] - A multi-dimensional approach focusing on transformation, innovation, enhancement, and strengthening has been adopted for the strategic planning [1] - The planning work is progressing in an orderly manner, indicating a structured approach to achieving its strategic objectives [1]

Group 1 - The company is effectively advancing its established strategic goals across various areas including market, research and development, and manufacturing [2]

Core Viewpoint - The company, Kangdelai (603987), is actively expanding its market presence through various sales models and channels, focusing on both domestic and international markets [1] Domestic Market - The company primarily utilizes an agency production model for its domestic market [1] International Market - For the international market, the company employs both entrusted export and self-operated export as its main sales models [1] - The company is committed to expanding its international market presence through multiple strategies [1]

证券代码：603987 证券简称：康德莱 公告编号：2025-030 上海康德莱企业发展集团股份有限公司 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 6 日（星期四）至 11 月 12 日（星期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 kdl@kdlchina.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 上海康德莱企业发展集团股份有限公司（以下简称"公司"）已于 2025 年 10 月 28 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了 解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 11 月 13 日（星 期四）15:00-16:30 参加 2025 年上海辖区上市公司三季报集体业绩说明会，就 投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年第三季度的经 营 ...

Core Viewpoint - 康德莱 is a leading enterprise in the medical device sector in China, specializing in medical puncture needles and related products, with a strong full-industry chain advantage and superior product quality and technology [1] Group 1: Business Performance - In Q3 2025, 康德莱 reported revenue of 1.721 billion yuan, ranking 15th among 50 companies in the industry, while the industry leader, 英科医疗, achieved revenue of 7.425 billion yuan [2] - The net profit for the same period was 214 million yuan, also ranking 15th in the industry, with the top performer, 乐普医疗, reporting a net profit of 996 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, 康德莱's debt-to-asset ratio was 28.00%, down from 29.49% year-on-year, which is higher than the industry average of 23.66% [3] - The gross profit margin for Q3 2025 was 32.59%, an increase from 31.30% year-on-year, but still below the industry average of 48.78% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 29.67% to 34,100, while the average number of circulating A-shares held per shareholder decreased by 22.88% to 12,800 [5] - New significant shareholders include 招商成长量化选股股票A and 医疗器械ETF, while 国寿安保智慧生活股票A and 招商量化精选股票发起式A exited the top ten circulating shareholders list [5] Group 4: Executive Compensation - The chairman, 张宪淼, maintained a salary of 1 million yuan for 2024, while the general manager, 张维鑫, saw a salary increase to 1.2278 million yuan, up by 347,800 yuan from 2023 [4]